Autopsy report · NCT00738881

Pemetrexed Disodium or Erlotinib Hydrochloride as Second-Line Therapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Slow accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 6 years 2 months before it stopped.
23 participants enrolled.
Results were posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: National Cancer Institute (NCI)
Sponsor type: US National Institutes of Health
Conditions: Recurrent Non-Small Cell Lung Carcinoma; Stage IIIA Non-Small Cell Lung Cancer; Stage IIIB Non-Small Cell Lung Cancer; Stage IV Non-Small Cell Lung Cancer
Interventions: Erlotinib Hydrochloride; Pemetrexed Disodium
Participants: 23
Sites: 269
Countries: Canada, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.